Investments & digital assets › F8949.A.X16
F8949.A.X16 · federal · F8949 line A.X16
Delmar Pharma (acquired 2025-07-17, sold 2025-11-19; proceeds 738.78, basis 717.05)
21.73
engine v3
not yet verified
How this number was built
R-8949-LOT One line per sale: proceeds minus basis plus adjustment. Broker basis is used as reported unless a supplemental statement for the same lot is matched.
Sources (6) — where the inputs came from
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 25 · field X16_desc · “Lot X16 description”
read as “Delmar Pharma” → Delmar Pharma
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 25 · field X16_acq · “Lot X16 date acquired”
read as “07/17/2025” → 2025-07-17
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 25 · field X16_sold · “Lot X16 date sold”
read as “11/19/2025” → 2025-11-19
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 25 · field X16_proceeds · “Lot X16 proceeds”
read as “738.78” → 738.78
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 25 · field X16_basis · “Lot X16 cost basis”
read as “717.05” → 717.05
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 25 · field X16_wash · “Lot X16 wash sale loss disallowed”
read as “0.00” → 0
99%
Flows into
History — nothing is overwritten
v1 · 2026-03-04: 21.73v2 · 2026-03-19: 21.73v3 · 2026-06-23: 21.73
Adjust this number
Evidence & discussion
Record how you verified it